Fábio Franke

18.1k total citations · 2 hit papers
54 papers, 2.0k citations indexed

About

Fábio Franke is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Fábio Franke has authored 54 papers receiving a total of 2.0k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Pulmonary and Respiratory Medicine, 38 papers in Oncology and 9 papers in Cancer Research. Recurrent topics in Fábio Franke's work include Advanced Breast Cancer Therapies (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Fábio Franke is often cited by papers focused on Advanced Breast Cancer Therapies (14 papers), Lung Cancer Treatments and Mutations (14 papers) and Cancer Immunotherapy and Biomarkers (10 papers). Fábio Franke collaborates with scholars based in United States, Brazil and Germany. Fábio Franke's co-authors include Carlos H. Barrios, Lucio Crinò, G. Jeannin, Paul D. Smith, Alice T. Shaw, Pasi A. Jänne, José Rodrigues Pereira, Lynda Grinsted, Johan Vansteenkiste and Victoria Zazulina and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Fábio Franke

51 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer

2019 591 citations Seock‐Ah Im, Yen‐Shen Lu et al. profile →
Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study

2012 512 citations Pasi A. Jänne, Alice T. Shaw et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Fábio Franke United States	19	1.4k	1.3k	558	535	183	54	2.0k
James A. Reeves United States	17	1.4k 1.0×	1.7k 1.3×	926 1.7×	351 0.7×	276 1.5×	59	2.6k
Walter Bordogna Switzerland	22	2.1k 1.5×	1.8k 1.3×	827 1.5×	584 1.1×	122 0.7×	49	2.6k
Lorenza Landi Italy	22	1.0k 0.7×	1.1k 0.9×	611 1.1×	423 0.8×	90 0.5×	85	1.8k
Kathryn H. Brown United Kingdom	15	1.8k 1.2×	1.4k 1.1×	931 1.7×	460 0.9×	95 0.5×	30	2.4k
Katarína Petráková Czechia	23	1.4k 1.0×	2.1k 1.6×	645 1.2×	989 1.8×	301 1.6×	66	2.8k
Pascale Tomasini France	22	1.1k 0.8×	1.1k 0.9×	465 0.8×	425 0.8×	69 0.4×	109	1.8k
Puyuan Xing China	22	1.0k 0.7×	1.2k 0.9×	461 0.8×	295 0.6×	86 0.5×	149	1.7k
Craig H. Reynolds United States	21	1.3k 0.9×	1.3k 1.0×	468 0.8×	279 0.5×	95 0.5×	57	2.0k
Annetta Krebs United States	8	1.9k 1.3×	2.0k 1.5×	723 1.3×	395 0.7×	117 0.6×	8	2.8k

Countries citing papers authored by Fábio Franke

Since Specialization

Citations

This map shows the geographic impact of Fábio Franke's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fábio Franke with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fábio Franke more than expected).

Fields of papers citing papers by Fábio Franke

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fábio Franke. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fábio Franke. The network helps show where Fábio Franke may publish in the future.

Co-authorship network of co-authors of Fábio Franke

This figure shows the co-authorship network connecting the top 25 collaborators of Fábio Franke. A scholar is included among the top collaborators of Fábio Franke based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fábio Franke. Fábio Franke is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okamoto, Isamu, Shoichi Kuyama, Nicolas Girard, et al.. (2024). TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncology. 20(37). 2927–2936. 6 indexed citations

Harper‐Wynne, Catherine, Yeon Hee Park, Fábio Franke, et al.. (2024). heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer. 24(1). 641–641. 4 indexed citations

Küemmel, Sherko, Catherine Harper‐Wynne, Fábio Franke, et al.. (2023). Abstract OT2-03-01: heredERA Breast Cancer: Phase III study of first-line, fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection ± giredestrant (GDC-9545) for estrogen receptor+, HER2+ advanced breast cancer. Cancer Research. 83(5_Supplement). OT2–3. 2 indexed citations

Okamoto, Isamu, Shoichi Kuyama, Nicolas Girard, et al.. (2023). 1505TiP TROPION-Lung07: A phase III trial of datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy in advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) with PD-L1 expression. Annals of Oncology. 34. S847–S848. 3 indexed citations

Munhoz, Rodrigo Ramella, Guilherme Nader Marta, Veridiana Pires de Camargo, et al.. (2022). A phase 2 study of first‐line nivolumab in patients with locally advanced or metastatic cutaneous squamous‐cell carcinoma. Cancer. 128(24). 4223–4231. 27 indexed citations

Diab, Adi, Helen Gogas, Shahneen Sandhu, et al.. (2022). 785O PIVOT IO 001: First disclosure of efficacy and safety of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) vs NIVO monotherapy in advanced melanoma (MEL). Annals of Oncology. 33. S901–S901. 8 indexed citations

Bardia, Aditya, Fei Su, Nadia Solovieff, et al.. (2021). Genomic Profiling of Premenopausal HR+ and HER2– Metastatic Breast Cancer by Circulating Tumor DNA and Association of Genetic Alterations With Therapeutic Response to Endocrine Therapy and Ribociclib. JCO Precision Oncology. 5(5). 1408–1420. 24 indexed citations

Shitara, Kohei, Fábio Franke, Yoshiaki Kawaguchi, et al.. (2021). 1436TiP Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-positive gastric cancer (GC) or gastroesophageal junction (GEJ) adenocarcinoma who have progressed on or after a trastuzumab-containing regimen (DESTINY-gastric04, DG-04): A randomized phase III study. Annals of Oncology. 32. S1073–S1073. 4 indexed citations

Saad, Fred, Eleni Efstathiou, Gerhardt Attard, et al.. (2021). Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. The Lancet Oncology. 22(11). 1541–1559. 64 indexed citations

10.

Cronemberger, Eduardo, Clarissa Baldotto, Pedro De Marchi, et al.. (2020). Real-World Molecular Testing and Treatment Patterns in Brazilian Patients with Newly Diagnosed Locally Advanced or Metastatic NSCLC. Clinics. 75. e1777–e1777. 6 indexed citations

11.

Shparyk, Yaroslav, Igor Bondarenko, Giovanni M. Bariani, et al.. (2018). Bevacizumab biosimilar BEVZ92 versus reference bevacizumab in combination with FOLFOX or FOLFIRI as first-line treatment for metastatic colorectal cancer: a multicentre, open-label, randomised controlled trial. The Lancet. Gastroenterology & hepatology. 3(12). 845–855. 34 indexed citations

12.

Tripathy, Debu, Aditya Bardia, Sara A. Hurvitz, et al.. (2015). Phase III, randomized, double-blind, placebo-controlled study of ribociclib (LEE011) in combination with either tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with HR+, HER2- advanced breast cancer (aBC): MONALEESA-7.. Journal of Clinical Oncology. 33. 6 indexed citations

13.

Jänne, Pasi A., Ian C. P. Smith, Gael McWalter, et al.. (2015). Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer. British Journal of Cancer. 113(2). 199–203. 59 indexed citations

14.

Jänne, Pasi A., Alice T. Shaw, José Rodrigues Pereira, et al.. (2012). Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. The Lancet Oncology. 14(1). 38–47. 512 indexed citations breakdown →

15.

Belani, Chandra P., Thomas Brodowicz, Tudor–Eliade Ciuleanu, et al.. (2012). Quality of life in patients with advanced non-small-cell lung cancer given maintenance treatment with pemetrexed versus placebo (H3E-MC-JMEN): results from a randomised, double-blind, phase 3 study. The Lancet Oncology. 13(3). 292–299. 56 indexed citations

16.

Laskin, Janessa, Lucio Crinò, Enriqueta Felip, et al.. (2011). Safety and Efficacy of First-Line Bevacizumab Plus Chemotherapy in Elderly Patients with Advanced or Recurrent Nonsquamous Non-small Cell Lung Cancer: Safety of Avastin in Lung trial (MO19390). Journal of Thoracic Oncology. 7(1). 203–211. 50 indexed citations

17.

Smith, Ian E., Jean‐Yves Pierga, Laura Biganzoli, et al.. (2010). First-line bevacizumab plus taxane-based chemotherapy for locally recurrent or metastatic breast cancer: safety and efficacy in an open-label study in 2251 patients. Annals of Oncology. 22(3). 595–602. 81 indexed citations

18.

Zandwijk, Nico van, et al.. (2008). Biomarker analyses from an open-label study of erlotinib in advanced non-small-cell lung cancer (NSCLC). Journal of Clinical Oncology. 26(15_suppl). 19012–19012. 2 indexed citations

19.

Segalla, J. G. M., et al.. (2008). Evaluation of Quality of Life in Patients with Metastatic Colorectal Cancer Treated with Capecitabine. Clinical Colorectal Cancer. 7(2). 126–133. 10 indexed citations

20.

Guecheva, Temenouga Nikolova, Fábio Franke, Carina Cassini, et al.. (2007). Association of low repair efficiency with high hormone receptors expression and SOD activity in breast cancer patients. Clinical Biochemistry. 40(16-17). 1252–1258. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact